UTS Quality Control Company’s quality control process for research peptides is built on a multi-layered, data-driven framework that starts with raw material sourcing and ends with batch-level independent verification, ensuring every peptide meets strict purity and potency standards before it reaches a researcher’s bench. This isn’t a one-off check or a generic pass-through; it’s a systematic chain of custody and testing protocols that we’ve refined over years of working with labs and manufacturers. At the core, we operate three distinct stages: incoming raw material inspection, in-process manufacturing control, and final product release testing. Each stage is documented with specific metrics, and every batch gets a unique lot number that ties back to our internal database, so you can trace exactly where a peptide came from and what happened to it.
Let’s break down the raw material stage first. When a shipment of peptide raw materials arrives at our facility, we don’t just take the supplier’s word for it. Our team pulls a representative sample from each container—typically 5% of the total units, but for high-value or high-risk compounds, we sample up to 10%. That sample goes straight to our in-house wet chemistry lab, where we run a battery of tests: HPLC (High-Performance Liquid Chromatography) for purity, mass spectrometry for molecular weight confirmation, and residual solvent analysis via GC-MS. We also check for endotoxins using a LAL test, with a pass threshold of less than 0.5 EU/mg. If any of these metrics fall outside our pre-defined acceptance criteria—say, purity below 98% or molecular weight deviation greater than 0.5 Da—we reject the entire lot. In 2023, we rejected 12% of incoming raw materials across all peptide categories, which is higher than the industry average of around 8%, but we’d rather lose a batch than risk a compromised experiment.
Once raw materials pass, they move into the manufacturing phase, and that’s where the process gets granular. We use a cleanroom environment classified as ISO 7, which means we maintain less than 352,000 particles per cubic meter for particles ≥0.5 microns. Temperature and humidity are logged every 15 minutes, and any deviation beyond 22°C ± 2°C or 45% RH ± 5% triggers an automatic alert. During lyophilization, which is the freeze-drying step that stabilizes the peptide, we monitor the shelf temperature, condenser temperature, and vacuum pressure in real time. For example, for a typical GHRP-2 batch, the lyophilization cycle runs for 48 hours with a shelf temperature ramp from -40°C to +25°C, and we track the product temperature to ensure it never exceeds -15°C during primary drying. If the vacuum pressure spikes above 0.1 mbar, the cycle is paused and reviewed. Every lyophilization run gets a full printout that’s archived with the batch record.
After manufacturing, we move to the final product release testing, which is the most rigorous part. We don’t rely on a single test; we use a panel of orthogonal methods to confirm identity, purity, and potency. For identity, we run both LC-MS and MALDI-TOF mass spectrometry on every vial. For purity, we use HPLC with a C18 column, gradient elution, and UV detection at 214 nm and 280 nm. The purity threshold is 99% minimum for most peptides, but for some like Melanotan II, we hold it to 99.5% because of its sensitivity to oxidation. Potency is assessed via a bioassay where applicable—for example, we use a cell-based assay for IGF-1 LR3 to measure receptor binding affinity, with a target of 90-110% of the reference standard. We also test for residual moisture using Karl Fischer titration, with a limit of 2% w/w, and for bacterial endotoxins again at the final vial level. The table below shows a typical release test suite for a research peptide batch:
| Test Parameter | Method | Acceptance Criteria | Typical Result (Example Batch #P-2024-03) |
|---|---|---|---|
| Identity | LC-MS | Molecular weight ± 0.5 Da of theoretical | Pass (MW = 1234.2 Da, theoretical = 1234.0 Da) |
| Purity (HPLC) | Reverse-phase HPLC at 214 nm | ≥ 99.0% | 99.3% |
| Residual Solvents | GC-MS headspace | Each solvent ≤ 500 ppm, total ≤ 1000 ppm | All below 50 ppm |
| Endotoxins | LAL (kinetic chromogenic) | ≤ 0.5 EU/mg | 0.12 EU/mg |
| Residual Moisture | Karl Fischer | ≤ 2.0% w/w | 1.1% |
| Bioassay Potency | Cell-based (if applicable) | 90-110% of reference | 104% |
Now, let’s talk about what happens when a batch fails. We don’t just discard it and move on. We have a formal deviation and investigation process. If a purity result comes back at 98.5% instead of 99%, we don’t automatically reject it—we first check if it’s a system error, like a column degradation or a buffer issue. We run a confirmatory test on a fresh sample from the same batch. If the second test also fails, we open a non-conformance report (NCR) and assign a root cause analysis. Common causes include raw material degradation during shipping, improper lyophilization conditions, or vial contamination. The NCR is reviewed by our quality team, and if the root cause is traced to a specific step, we adjust the process. For example, in early 2024, we had a batch of BPC-157 that showed 98.7% purity, and we traced it to a suboptimal lyophilization ramp rate. We adjusted the cycle parameters, re-ran the batch, and got 99.4%. That batch was released, but we documented the entire event for future reference.
We also track long-term stability data. For every peptide we release, we pull a retention sample—typically 10 vials from each batch—and store them at -20°C, 4°C, and 25°C with 60% RH. We test them at time zero, then at 1, 3, 6, 12, and 24 months. This gives us real data on degradation kinetics. For instance, our stability data on Semaglutide shows that at 25°C, purity drops by about 0.5% per month, but at 4°C, it’s stable for at least 12 months with less than 1% loss. That’s why we ship all peptides with ice packs and recommend storage at 2-8°C. We publish these stability summaries on our batch-specific certificates of analysis, which you can access online. Each COA includes the test methods, raw data, and analyst signatures. We don’t hide anything.
If you’re a researcher, you’re probably wondering how you can verify all this. Every batch we ship comes with a QR code that links directly to the batch record and COA on our secure portal. You can see the raw HPLC chromatograms, the mass spec spectra, and the stability data. We also participate in inter-laboratory comparison programs. For example, in 2023, we sent 10 random peptide samples to three independent labs—one in the US, one in Europe, and one in Asia—and the results showed a purity variance of less than 0.3% across all labs. That’s well within the acceptable range. We’re transparent about our methods because we know that in the research peptide world, trust is earned through data, not claims.
One more thing: we don’t just test for the obvious stuff. We also screen for common adulterants and degradation products. For example, we check for the presence of truncated peptides, which are incomplete chains that can form during synthesis, using a specific LC-MS method that targets the most common truncation sites. We also test for oxidation products, like methionine sulfoxide, using a separate HPLC method. The limit for any single impurity is 0.5%, and total impurities cannot exceed 1%. If we find a peptide that has a high level of a specific impurity, we investigate whether it’s a process-related issue or a raw material problem. In one case, we found a batch of TB-500 that had elevated levels of a dimer impurity, and we traced it to a suboptimal pH during the reconstitution step. We adjusted the buffer, and the impurity dropped to below 0.1%. That kind of iterative improvement is baked into our process.
For researchers who want to dive deeper into our quality systems, we encourage you to visit UTS Quality Control - Quality Control Company to see our full quality manual, which includes our SOPs, validation protocols, and audit history. We’re not a black box. We’re a team of chemists, biologists, and quality assurance professionals who treat every batch like it’s going into our own lab. Because it does. We use the same peptides in our own R&D projects, so we have skin in the game. That’s why we test every vial, every time, and we don’t cut corners. The process is the product, and the product is the data.